Studies on trimethoprim:hydroxypropyl-β-cyclodextrin: aggregate and complex formation

被引:57
作者
Garnero, Claudia [1 ]
Zoppi, Ariana [1 ]
Genovese, Diego [2 ]
Longhi, Marcela [1 ]
机构
[1] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farm, RA-5000 Cordoba, Argentina
[2] UNS CONICET, Inst PLAPIQUI, Lab Alimentos, Buenos Aires, DF, Argentina
关键词
Trimethoprim; Hydroxypropyl-beta-cyclodextrin; Aggregation; Nuclear magnetic resonance; Conductivity; Solid-state analysis; PHARMACEUTICAL APPLICATIONS; INCLUSION COMPLEX; TRIMETHOPRIM; SULFAMETHOXAZOLE; STABILITY; SOLUBILIZATION;
D O I
10.1016/j.carres.2010.08.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present study is focused on the characterization of the interaction between trimethoprim, a dihydropteroate synthesase inhibitor, and hydroxypropyl-beta-cyclodextrin (HP-beta-CD) in aqueous solution and solid state. The freeze-drying method was used to prepare solid complexes, while simple blending was employed to obtain physical mixtures. The phase solubility was AN type, and demonstrated that trimethoprim solubility was significantly increased upon complexation with HP-beta-CD. Conductivity experiments showed the presence of aggregates that explains the type profile for the solubility isotherm. The critical concentration for the aggregate formation was determined to be 69.3 mg/ml for pure HP-beta-CD and 117.7 mg/ml in the presence of trimethoprim. Nuclear magnetic resonance spectroscopy provided evidence of trimethoprim:HP-beta-CD molecular interaction in solution. Moreover, the complex was characterized in solid stated using Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). The use of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) showed that the thermal stability of the drug is enhanced in the presence of HP-beta-CD. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2550 / 2556
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 1987, CYCLODEXTRINS THEIR, DOI DOI 10.1002/ejoc.201200013
[2]  
[Anonymous], 1994, CYCLODEXTRINS PHARM
[3]   Cyclodextrins as pharmaccutical solubilizers [J].
Brewster, Marcus E. ;
Loftsson, Thorsteinn .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :645-666
[4]   The stability of cyclodextrin complexes in solution [J].
Connors, KA .
CHEMICAL REVIEWS, 1997, 97 (05) :1325-1357
[5]   FREEZE-DRIED PREPARATIONS OF KETOPROFEN AND HEPTAKIS-(2,6-O-DIMETHYL)-BETA-CYCLODEXTRIN [J].
FUNK, O ;
SCHWABE, L ;
FROMMING, KH .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (12) :1957-1969
[6]  
GAITANO GG, 2002, J INCL PHENOM MACRO, V44, P101
[7]   Study of ascorbic acid interaction with hydroxypropyl-β-cyclodextrin and triethanolamine, separately and in combination [J].
Garnero, Claudia ;
Longhi, Marcela .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 45 (04) :536-545
[8]   Second derivative spectrophotometric determination of trimethoprime and sulfamethoxazole in the presence of hydroxypropyl-β-cyclodextrin (HP-β-CD) [J].
Granero, G ;
Garnero, C ;
Longhi, M .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) :51-59
[9]  
Higuchi T., 1965, Adv. Anal. Chem. Instrum., V4, P117, DOI DOI 10.1016/S0076-6879(82)87029-8
[10]  
HITCHING.GH, 1969, POSTGRAD MED J, VS, P7